Natera stock

NTRA · NASDAQ · USD

$319.09Change from previous close: −1.19%Absolute change: −$3.85

Close · November 13, 2026

Price history

+59.01% over the period

1 year: from $200.67 (November 13, 2025) to $319.09 (November 13, 2026), +59.01%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$319.09
October 30, 2026$414.30
September 30, 2026$413.31
August 31, 2026$321.96
July 31, 2026$267.76
June 30, 2026$271.45
May 29, 2026$223.37
April 30, 2026$206.16
March 31, 2026$199.99
February 27, 2026$208.04
January 30, 2026$231.14
December 31, 2025$229.09
November 28, 2025$238.81
November 13, 2025$200.67

At a glance

  • The company

    Develops and commercializes molecular diagnostic tests for cancer, prenatal screening and transplant monitoring worldwide

  • Latest results

    Quarter to September 30, 2026 · EPS -$0.42 (estimate -$0.27)

TickerLandia's take on Natera

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$181.00
52-wk high$437.41

−27.05% from the 52-week high

Analysts · 22 analysts

Average target$410.26+28.57% vs. price

Buy 20 · Hold 2 · Sell 0 · Strong buy

TickerLandia Fingerprint: Natera

Compared with similar companies: very low earnings stability, very high price, and very strong momentum.

Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Natera is pricier than similar companies

Natera's Price/book: 24.6, +196% against the median of a group of 10 similar companies (8.33).

Compared with 11 similar companies

Natera's metrics compared with similar companies
MetricNateraPosition in the groupBand
Operating margin-8.5%Low
ROE-10.6%Low
Debt/equity0.13Low
Price/book24.6Middle
Net margin-5.7%Low

Grey band: the middle half of the group; tick: the median; dot: Natera. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$752.75M

Latest quarter · Q2 2026

Net income

-$66.97M

Latest quarter · Q2 2026

Quarterly net margin

-8.9%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$46.27B
EPS
-$1.12
Volume
1.69M
Daily trading
€708.69M

How Natera is changing

All results
  • Revenue grew 42.6% a year on average over the last 5 years

  • Operating margin rose from −66.0% to −13.4%

  • Shares outstanding up 68.8% in 5 years

Returns

Natera returns

$1,000 invested in Natera 5 years ago, on November 15, 2021, would be worth $2,754 today: +175.43% in total, +22.49% per year. This is the price return only: dividends are excluded.

PeriodNateraS&P 500$1,000 becomes
1 month−19.35%−3.12%$806
6 months+63.37%+1.58%$1,634
Year to date+39.29%+10.46%$1,393
1 year+59.01%+12.23%$1,590
3 years+557.38%+71.41%$6,574
5 years+175.43%+61.48%$2,754
10 years+2,650.78%+249.40%$27,508

Over the last 6 months it has done better than 93% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Natera: technical analysis

Natera shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 26.8% below its all-time closing high ($436.00, October 29, 2026).

Trend
No clear trend
RSI (14 sessions)
34
Between 30 and 70
vs 200-session average
+17.59%

Support and resistance

Price areas where Natera has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$436.80+36.89%2 touches, last on October 29, 2026
  2. Resistance$382.08+19.74%2 touches, last on October 22, 2026
  3. Resistance$321.01+0.60%2 touches, last on August 31, 2026
  4. Last price$319.09
  5. Support$304.50−4.57%2 touches, last on November 6, 2026
  6. Support$258.99−18.83%2 touches, last on July 13, 2026
  7. Support$245.49−23.06%4 touches, last on July 29, 2026

Volatility and risk

Over the last year it has moved more than the S&P 500.

Beta (1 year) vs S&P 500
1.30
Volatility (60 sessions, annualised)
54.7%
Largest fall in the last year
−28.75%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Natera: seasonality

Average monthly price change over 12 years

−1.8%Jan+1.9%Feb+0.2%Mar+3.6%Apr+9.7%May+12.7%Jun−0.0%Jul+15.7%Aug−2.2%Sep−3.5%Oct+10.0%Nov−0.1%Dec

Over the last 12 years, the strongest month for Natera has been August: +15.72% on average, positive in 10 years out of 12. The weakest has been October: −3.49% on average, positive in 5 years out of 12. November, the current month, has been positive in 6 years out of 11 (+10.05% on average).

Show chart data
MonthAverageMedianPositive years
January−1.79%+3.92%7 of 11
February+1.91%+6.70%6 of 11
March+0.20%−3.87%5 of 11
April+3.58%+3.09%8 of 11
May+9.73%+8.35%9 of 11
June+12.71%+7.11%9 of 11
July−0.01%−1.36%4 of 11
August+15.72%+19.86%10 of 12
September−2.17%−2.39%5 of 12
October−3.49%−5.81%5 of 12
November+10.05%+7.76%6 of 11
December−0.08%−2.42%4 of 11

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Natera and its competitors

Based in Austin, Texas, Natera was founded in 2003 and develops and commercializes molecular testing services. Its portfolio includes Signatera, a personalized ctDNA blood test used for MRD assessment and early recurrence monitoring, alongside Panorama, a non-invasive prenatal test, and Prospera, a test for active rejection in patients with solid organ transplants. Its customers include independent and reference laboratories, medical centers, physician practices, research laboratories and pharmaceutical companies, reached through a direct sales force, laboratory distribution partners and Constellation licensees.

Headquarters
Austin, United States
Employees
6,135
Founded
2003
Chief executive
Steven Chapman
Natera and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
NateraNTRA$46.27B-8.5%—+63.37%
IQVIA HoldingsIQV$43.69B13.9%32.3+53.80%
Agilent TechnologiesA$49.04B24.5%34.3+54.30%
IDEXX LaboratoriesIDXX$55.48B32.5%47.0+33.21%
Mettler-Toledo InternationalMTD$34.59B27.8%37.7+69.56%
IlluminaILMN$31.3B19.1%36.1+42.77%

Same industry or related industries, similar size. Compare Natera with its competitors · Full profile